Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study

Ann‐Lii Cheng; Yoon‐Koo Kang; Aiwu Ruth He; Ho Yeong Lim; Baek‐Yeol Ryoo; Chao‐Hung Hung; I‐Shyan Sheen; Namiki Izumi; TaShara Austin; Qiang Wang; Jonathan Greenberg; Shinichi Shiratori; Robert A. Beckman; Masatoshi Kudo

doi:10.1016/j.jhep.2015.06.001

Related publications

Article2014

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Andrew X. Zhu, Baek‐Yeol Ryoo, Chung‐Jen Yen, Masatoshi Kudo, Ronnie T. P. Poon, Davide Pastorelli, J.-F. Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shan‐Chwen Chang, Paolo Abada, Lifen Yang, Jonathan D. Schwartz, Joon Oh Park

Article2024

Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Richard S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Anran Wang, Kalgi Mody, Leonid Dubrovsky, Abby B. Siegel, Josep M. Llovet

Journal of Clinical Oncology

Article2020

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Tami Wisniewski, Jeffrey Anderson, Chiun Hsu

Article2012

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet

Journal of Hepatology

Article2015

Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.

Masafumi Ikeda, Satoshi Shimizu, Tosiya Sato, Manabu Morimoto, Yoshitaka Inaba, Yasushi Kojima, Atsushi Hagihara, Masatoshi Kudo, Shoji Nakamori, Shuichi Kaneko, Rie Sugimoto, Toshiyuki Tahara, Takumi Ohmura, Kohichiroh Yasui, Keiko Sato, Hiroshi Ishii, Junji Furuse, Takuji Okusaka